Bepirovirsen
Chronic hepatitis B · Adults with chronic hepatitis B
GSK · GSK plc
Regulatory designations
Full timeline
8 milestonesFDA approved Hibsago (bepirovirsen)
FDA approved Hibsago in combination with existing antiviral therapy for certain adults without cirrhosis who have chronic hepatitis B, have received antiviral therapy for at least six months, have suppressed HBV DNA, and have HBsAg levels of 3,000 IU/mL or less.
FDA — Hibsago approval announcement↗FDA decision expected
FDA assigned an October 26, 2026 PDUFA goal date to the bepirovirsen NDA.
GSK — NDA acceptance and PDUFA date↗Detailed Phase 3 B-Well results were reported
Across B-Well 1 and B-Well 2, 19% of qualifying participants achieved functional cure at week 72 with bepirovirsen plus standard of care versus 0% with placebo plus standard of care.
GSK — Detailed B-Well 1 and B-Well 2 results↗FDA accepted the NDA with Priority Review
FDA accepted the application, granted Breakthrough Therapy designation and established the October goal date.
GSK — NDA acceptance and regulatory designations↗Related News
Velzatinib granted Orphan Drug Designation (ODD) in Japan in GIST
Nov 17, 2026Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer
Nov 13, 2026Bexsero (4CMenB) receives positive CHMP opinion for one-dose Meningitis B booster for 10+ year olds
Nov 5, 2026GSK showcases progress in liver portfolio at AASLD 2026
Oct 28, 2026GSK delivers strong Q3 performance and continued momentum
